CORE Biomedicine Secures $21 Million Series A Venture Financing and Receives AMED Grant Award to Advance Novel Cancer Therapeutics

CORE Biomedicine has successfully completed a $21 million Series A financing round aimed at advancing its innovative lineage-based oncology therapies. The funding, announced on July 28, 2026, was co-led by UTokyo Innovation Platform Co., Ltd. and Elikon Venture, with additional participation from notable investors including InnoPinnacle Fund, Mitsubishi UFJ Capital Co., Ltd., Suzhou Capital Group Co., Ltd., CD Capital, YuanBio Venture Capital, Vision Incubate Co., Ltd., and Root Venture Partners. This capital infusion is expected to significantly bolster CORE's research and development efforts in the competitive biotechnology sector.

Founded by former leaders of H3 Biomedicine, CORE Biomedicine is focused on developing precision oncology therapeutics that go beyond traditional genomic approaches. The company’s unique lineage-based strategy aims to identify and target core oncology drivers, potentially expanding the patient populations that could benefit from its therapies. This innovative approach positions CORE to address critical challenges in cancer treatment, particularly as the industry increasingly seeks to provide more personalized and effective therapies.

In conjunction with the Series A funding, CORE Biomedicine has also been awarded a grant from the Japan Agency for Medical Research and Development (AMED). This grant, part of AMED's Strengthening Program for Pharmaceutical Startup Ecosystem, is designed to support innovative biotech companies in Japan. The funding will enhance CORE's R&D activities, facilitating collaborations with Japanese universities, hospitals, and the broader biopharma community. Such partnerships are essential for advancing CORE's lead programs through the discovery and early clinical development stages.

The participation of multiple prominent investors in this financing round underscores the growing interest in biotechnology, particularly in the oncology sector. As the global biopharma landscape evolves, companies like CORE Biomedicine are at the forefront of developing solutions that address unmet medical needs. The strategic backing from both local and international investors reflects confidence in CORE's potential to deliver transformative therapies to patients worldwide.

Looking ahead, the successful completion of this financing round and the associated AMED grant position CORE Biomedicine favorably within the biotechnology sector. The company’s innovative approach to precision medicine, combined with robust financial support, may enhance its ability to navigate the complexities of drug development and clinical trials. As demand for effective cancer therapies continues to rise, CORE's advancements could contribute to shaping the future of oncology treatment and improving patient outcomes on a global scale.